Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020.

J Gynecol Oncol · 2021 · PMC8550929 · PMID 34708597

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

The GOG0213 trial ( NCT00565851 ) of the addition of bevacizumab to platinum-based chemotherapy after secondary surgical cytoreduction followed by maintenance therapy until progression, showed a marginally significant improvement in the median OS of women in this group compared to standard chemotherapy group (42.2 vs. 37.3 months) [ 76 ].

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.